StockData

Huntsman vs Innospec

HUN and IOSP side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HUN and IOSP compare

Innospec is the larger company, worth 1.2 times as much as Huntsman ($1.9B against $1.6B).

Innospec grew revenue faster over the last twelve months (2.9% versus 0.65% for Huntsman).

Both pay dividends: Huntsman yields 3.8% and Innospec 3.5%.

Innospec scores higher on the StockData Score (13 against 7 for Huntsman), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHUNIOSP
Size and price
Market cap$1.6B$1.9B
Share price$9.19$78.01
Change, 1 year5.6%5.3%
Change, 5 years−71.8%−6.2%
Beta (5Y)0.641.10
Employees6,0002,450
StockData Score
Total score713 (better)
Valuation score23 (better)
Growth score11
Performance score2 (better)1
Health score16 (better)
Dividend score12 (better)
Valuation
P/S0.3× (better)1.0×
P/B0.6× (better)1.4×
EV/EBITDA13.6×9.9× (better)
FCF yield−0.56%–
Fair value$10.85$92.08
Margin of safety15.3%15.3% (better)
Growth
Revenue growth (TTM)0.65%2.9% (better)
Revenue growth, 5Y average0.95%8.3% (better)
EPS growth, 5Y average–32.1%
Profitability
Gross margin13.5%27.5% (better)
Operating margin−0.54%7.0% (better)
Net margin−3.1%–
FCF margin−0.15%–
Return on equity−6.5%–
Return on invested capital−0.57%10.4% (better)
Financial health
Debt / equity0.78 (better)0.00
Net debt / EBITDA6.59–
Current ratio1.332.78 (better)
Altman Z-score1.464.85 (better)
Piotroski F-score2–
Dividends and buybacks
Dividend yield3.8% (better)3.5%
Years of dividend growth012 (better)
Dividend growth, 5Y average5.2%10.5% (better)
Buyback yield–1.3%
Shareholder yield3.8%4.8% (better)
Ownership
Held by institutions88.7%101%
Held by insiders6.7%1.6%
Insider net buying, 12 months$981K (better)−$874K
Short interest, % of float7.4%1.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.